AevisBio
Latest round
- Series A
Last raised
- Sep 2021
Total raised
- $8.6M
Investors
- 3
About AevisBio
Based in Daejeon, South Korea, and founded in 2018, AevisBio provides a scientific solution for drug development targeting incurable diseases such as inflammatory diseases, neurological disorders, and drug-resistant cancers. The company is building a portfolio of proteolytic drugs based on a novel immunomodulatory amide or IMiD low-molecular compound. Based on IMiD materials, AevisBio is conducting preclinical development targeting degenerative brain diseases such as traumatic brain injury or TBI and licensed the exclusive right to IMiD pomalidomide derivative-related pharmaceutical technology for use as a TPD precursor from the US National Institutes of Health in January 2021. The company develops and manufactures PROTAC, a bivalent proteolytic anticancer drug treatment of intractable diseases based on an immunomodulatory molecule (IMiD) compound. AevisBio plans to expand its indications to inflammatory diseases based on the inflammation-regulating action of IMiD.
Who invested in AevisBio
3 investors across 1 round
See all investors in AevisBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 6, 2021
Amount
$8.6M
Investors
Questions about AevisBio
Who invested in AevisBio?
AevisBio has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AevisBio raised?
AevisBio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did AevisBio last raise money?
AevisBio's most recent round on record is a Series A, in Sep 2021.
What does AevisBio do?
Based in Daejeon, South Korea, and founded in 2018, AevisBio provides a scientific solution for drug development targeting incurable diseases such as inflammatory diseases, neurological disorders, and drug-resistant cancers.
Where is AevisBio headquartered?
AevisBio is headquartered in Daejeon, South Korea.
Which VCs invest in companies like AevisBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at AevisBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like AevisBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.